PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Clinical trial NCT05311566 · UNKNOWN

Trial details

NCT number: NCT05311566
Sponsor: Lei Li
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Cervical Carcinoma Chemoradiotherapy Anti-programmed Cell Death Receptor 1 Immunotherapy Immune Checkpoint Inhibitor Survival Outcomes Adverse Events Early Stage Cervical Cancer Locally Advanced Cervical Cancer

Start date: 2022-03-27
Primary completion: 2023-03-27
Enrollment: 92

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.